MF-Az Nasal Spray Improves Allergic Rhinitis Symptoms in India Study
A real-world study in India found that mometasone furoate-azelastine nasal spray significantly improved nasal and non-nasal symptoms of allergic rhinitis.
July 27, 2026
1 min read
8 views
Source: emjreviews.com
A large real-world study conducted in India has demonstrated that a combination nasal spray containing mometasone furoate and azelastine (MF-Az) effectively improves both nasal and non-nasal symptoms in patients with allergic rhinitis. Allergic rhinitis is an IgE-mediated inflammatory condition that affects millions worldwide.
The study, which included a significant number of participants, evaluated the efficacy of the MF-Az nasal spray in a real-world setting, reflecting typical clinical practice. Results showed notable improvements in symptoms such as sneezing, nasal congestion, rhinorrhea, and itchy nose, as well as non-nasal symptoms like itchy eyes and throat.
Researchers emphasized that the combination therapy offers a convenient treatment option for patients who do not respond adequately to monotherapy. The findings support the use of MF-Az nasal spray as an effective intervention for managing allergic rhinitis symptoms.
❓ Frequently Asked Questions
What is allergic rhinitis?
Allergic rhinitis is an IgE-mediated inflammatory condition of the nasal mucosa triggered by allergens like pollen, dust mites, or pet dander, causing symptoms such as sneezing, congestion, and itchy eyes.
How does MF-Az nasal spray work?
MF-Az combines mometasone furoate, a corticosteroid that reduces inflammation, and azelastine, an antihistamine that blocks histamine release, providing dual action against allergic rhinitis symptoms.
What were the key findings of the India study?
The real-world study in India found that MF-Az nasal spray significantly improved both nasal and non-nasal symptoms of allergic rhinitis, supporting its use as an effective treatment option.
